Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2022Annals of the Rheumatic DiseasesOpen Access

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEileen W StalmanAmsterdam NeuroscienceLWLuuk WieskeSt. Antonius ZiekenhuisKDKoos P J van DamAmsterdam Neuroscience

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stalman et al. (2022) studied this question.

synapsesocial.com/papers/6aa905b3e4e7b17765d91a63https://doi.org/10.1136/ard-2022-222904
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant2022 · 430 citations
  2. 2Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-192022 · 125 citations
  3. 3Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost2021 · 376 citations
  4. 4Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease2021 · 270 citations
  5. 5Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies2020 · 444 citations